# Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

> **NCT03053102** · PHASE2 · COMPLETED · sponsor: **Alexion Pharmaceuticals, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria (PNH)

## Interventions

- **DRUG:** Danicopan

## Key facts

- **NCT ID:** NCT03053102
- **Lead sponsor:** Alexion Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-31
- **Primary completion:** 2018-11-14
- **Final completion:** 2018-11-14
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2022-06-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03053102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03053102, "Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03053102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*